Michelle Renee Griffin
Known title: DirectorCIK: 0001229765
Associated companies
Transaction History
| ADPT | ▲ Buy | Option Exercise | 52,084 | $406K | 6/25/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 52,084 | $1.1M | 6/25/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 15,394 | $214K | 3/11/2026 | View on chart |
| ADPT | ▲ Buy | Grant | 15,625 | $0 | 3/4/2026 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 48,044 | $192K | 3/3/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 48,044 | $735K | 3/3/2026 | View on chart |
| ADPT | ▼ Sell | Open Market | 36,291 | $261K | 3/13/2025 | View on chart |
| ADPT | ▼ Sell | Open Market | 15,664 | $124K | 3/6/2025 | View on chart |
| ADPT | ▲ Buy | Grant | 15,394 | $0 | 3/4/2025 | View on chart |
| ADPT | ▲ Buy | Grant | 31,328 | $0 | 3/4/2024 | View on chart |
| ADPT | ▼ Sell | Open Market | 2,341 | $20K | 3/27/2023 | View on chart |
| ADPT | ▲ Buy | Grant | 14,775 | $0 | 3/6/2023 | View on chart |
| ADPT | ▲ Buy | Grant | 6,689 | $0 | 1/26/2022 | View on chart |
| ADPT | ▲ Buy | Option Exercise | 14,916 | $116K | 8/27/2021 | View on chart |
| ADPT | ▼ Sell | Open Market | 14,916 | $522K | 8/27/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.